Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models.
GLP-1
IFALD
Liver fibrosis
Short bowel syndrome
TGF-β
Journal
Pediatric surgery international
ISSN: 1437-9813
Titre abrégé: Pediatr Surg Int
Pays: Germany
ID NLM: 8609169
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
accepted:
16
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
This study aimed to investigate the effectiveness of dipeptidyl peptidase IV inhibitors (DPP4-I) against liver damage, especially fibrosis and lipid accumulation, in a rat intestinal failure-associated liver disease (IFALD) model. SD rats were divided into two groups: the Control (n = 7; normal saline + IFALD model) and DPP4-I (n = 7; DPP4-I + IFALD model; short bowel syndrome (SBS) + total parenteral nutrition) groups. All rats were euthanized 21 days postoperatively to obtain tissue samples. Liver fibrosis was evaluated by Sirius Red and α-SMA staining. Liver damage was assessed using the steatosis, activity, and fibrosis score. Inflammation cytokines were examined by ELISA. The survival rate was comparatively different, being 87.5% in the DPP4-I group and 70.0% in the Control group. Two rats of the Control group showed progressive liver fibrosis in the periportal area with fibrous streaks. Further, the mean area percentage of α-SMA immune-positive cells was significantly lower in the DPP4-I group than in the Control group. TGF-β levels were significantly lower in the DPP4-I group than in the Control group. DPP4-I administration reduced liver fibrosis in IFALD, possibly by inhibiting DPP4-I-induced adipogenesis and suppressing TGF-β. These results may contribute to elucidating the mechanism of IFALD.
Identifiants
pubmed: 39470835
doi: 10.1007/s00383-024-05863-1
pii: 10.1007/s00383-024-05863-1
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP21K08605
Organisme : Japan Society for the Promotion of Science
ID : JP21K08605
Organisme : Japan Society for the Promotion of Science
ID : JP21K08605
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Duggan CP, Jaksic T (2017) Pediatric intestinal failure. N Engl J Med 377:666–675. https://doi.org/10.1056/NEJMra1602650
doi: 10.1056/NEJMra1602650
pubmed: 28813225
Lal S, Pironi L, Wanten G et al (2018) Clinical approach to the management of intestinal failure associated liver disease (IFALD) in adults: a position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. Clin Nutr 37:1794–1797. https://doi.org/10.1016/j.clnu.2018.07.006
doi: 10.1016/j.clnu.2018.07.006
pubmed: 30017241
Shakhsheer BA, Warner BW (2019) Short bowel syndrome. Curr Treat Options Pediatr 5:494–505. https://doi.org/10.1007/s40746-019-00179-y
doi: 10.1007/s40746-019-00179-y
pubmed: 33312846
pmcid: 7728382
Jeppesen PB, Sanguinetti EL, Buchman A et al (2005) Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54:1224–1231. https://doi.org/10.1136/gut.2004.061440
doi: 10.1136/gut.2004.061440
pubmed: 16099790
pmcid: 1774653
Chen L, Zhang X, Zhang L et al (2020) Effect of saxagliptin, a dipeptidyl peptidase 4 inhibitor, on non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes 13:3507–3518. https://doi.org/10.2147/DMSO.S262284
doi: 10.2147/DMSO.S262284
pubmed: 33116702
pmcid: 7547785
Hattori S, Nomoto K, Suzuki T et al (2021) Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Diabetol Metab Syndr 13:28. https://doi.org/10.1186/s13098-021-00644-5
doi: 10.1186/s13098-021-00644-5
pubmed: 33691757
pmcid: 7945344
Sueyoshi R, Furuhashi N, Ishii J et al (2022) Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition. Pediatr Surg Int 39:21. https://doi.org/10.1007/s00383-022-05301-0
doi: 10.1007/s00383-022-05301-0
pubmed: 36449115
Lauriti G, Zani A, Aufieri R et al (2014) Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. JPEN J Parenter Enteral Nutr 38:70–85. https://doi.org/10.1177/0148607113496280
doi: 10.1177/0148607113496280
pubmed: 23894170
Khalaf RT, Sokol RJ (2020) New insights into intestinal failure-associated liver disease in children. Hepatology 71:1486–1498. https://doi.org/10.1002/hep.31152
doi: 10.1002/hep.31152
pubmed: 32003009
El Kasmi KC, Anderson AL, Devereaux MW et al (2013) Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med 5:206ra137. https://doi.org/10.1126/scitranslmed.3006898
doi: 10.1126/scitranslmed.3006898
pubmed: 24107776
pmcid: 4070735
Onishi S, Kaji T, Yamada W et al (2016) The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome. Pediatr Surg Int 32:1165–1171. https://doi.org/10.1007/s00383-016-3975-1
doi: 10.1007/s00383-016-3975-1
pubmed: 27651372
Brinkman AS, Murali SG, Hitt S et al (2012) Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am J Physiol Gastrointest Liver Physiol 303:G610–G622. https://doi.org/10.1152/ajpgi.00184.2012
doi: 10.1152/ajpgi.00184.2012
pubmed: 22744334
pmcid: 3468558
Cavicchi M, Beau P, Crenn P et al (2000) Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 132:525–532. https://doi.org/10.7326/0003-4819-132-7-200004040-00003
doi: 10.7326/0003-4819-132-7-200004040-00003
pubmed: 10744588
Buchman AL, Naini BV, Spilker B (2017) The differentiation of intestinal-failure-associated liver disease from nonalcoholic fatty liver and nonalcoholic steatohepatitis. Semin Liver Dis 37:33–44. https://doi.org/10.1055/s-0036-1597771
doi: 10.1055/s-0036-1597771
pubmed: 28201847
Quigley EM, Marsh MN, Shaffer JL et al (1993) Hepatobiliary complications of total parenteral nutrition. Gastroenterology 104:286–301. https://doi.org/10.1016/0016-5085(93)90864-9
doi: 10.1016/0016-5085(93)90864-9
pubmed: 8419252
Tandra S, Yeh MM, Brunt EM et al (2011) Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 55:654–659. https://doi.org/10.1016/j.jhep.2010.11.021
doi: 10.1016/j.jhep.2010.11.021
pubmed: 21172393
Kaji K, Yoshiji H, Ikenaka Y et al (2014) Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol 49:481–491. https://doi.org/10.1007/s00535-013-0783-4
doi: 10.1007/s00535-013-0783-4
pubmed: 23475323
Di Dato F, Iorio R, Spagnuolo MI (2022) IFALD in children: what’s new? A narrative review. Front Nutr 9:928371. https://doi.org/10.3389/fnut.2022.928371
doi: 10.3389/fnut.2022.928371
pubmed: 35958249
pmcid: 9358220
Lefevre P, Cariou B, Lien F et al (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89:147–191. https://doi.org/10.1152/physrev.00010.2008
doi: 10.1152/physrev.00010.2008
Katsuma S, Hirasawa A, Tsujimoto G (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329:386–390. https://doi.org/10.1016/j.bbrc.2005.01.139
doi: 10.1016/j.bbrc.2005.01.139
pubmed: 15721318
Naimi RM, Hvistendahl MK, Thomassen LM et al (2021) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterol 8:e000604. https://doi.org/10.1136/bmjgast-2021-000604
doi: 10.1136/bmjgast-2021-000604
pubmed: 33975891
pmcid: 8117993